Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has announced a positive start to 2024 with preparations for FDA discussions on a pivotal breast cancer study, advancements in gastrointestinal cancer studies, and a solid cash position to support upcoming milestones. The company disclosed an encouraging cash reserve of $29.6 million, indicating a financial runway extending into 2025, and is set to release overall survival data from a key breast cancer study in the second half of the year. Oncolytics is optimistically progressing towards registration-enabling studies for its cancer treatment, pelareorep, in both breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
